Hospital CEO salaries have grown quickly over the past two decades. We investigate correlates of rising nonprofit hospital CEO pay between 2012 and 2019 by merging compensation data from Candid's IRS 990 forms with hospital data from the National Academy for State Health Policy Hospital Cost Tool. Almost half of the measured increase in CEO compensation (44.5%) accrued to a "base case" CEO, who was leading a non-teaching hospital system or independent hospital with fewer than 100 beds that earned 0 profits and provided no charity care. Another 28.5% of the measured salary increase resulted from changes in the generosity with which observable metrics were rewarded, particularly the reward for heading a system with 500 or more beds. The remaining 27% resulted mostly from hospital systems or single hospitals that increased their profits or bed size over time. The increase in CEO compensation associated with leading larger healthcare systems and earning greater profits may explain the increase in healthcare system consolidation which has occurred over the last several years.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268666 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0306571 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
The immunoglobulin of yolk and cerium oxide-based fibrous poly(L-lactide-co-glycolide)/gelatin dressings enable skin regeneration in an infectious wound model.
Mater Today Bio
February 2025
Department of Orthopedics, The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), NO.38, Wuyingshan Road, Tianqiao District, Jinan, 250031, China.
The bacterial infection and oxidative wound microenvironment delay skin repair and necessitate intelligent wound dressings to enable scarless wound healing. The immunoglobulin of yolk (IgY) exhibits immunotherapeutic potential for the potential treatment of antimicrobial-resistant pathogens, while cerium oxide nanoparticles (CeO NPs) could scavenge superoxide dismutase (SOD) and inflammation. The overarching objective of this study was to incorporate IgY and CeO NPs into poly(L-lactide-co-glycolide)/gelatin (PLGA/Gel)-based dressings (P/G@IYCe) for infected skin repair.
View Article and Find Full Text PDFRisk factors of recurrent periprosthetic joint infection of the knee after two-stage reimplantation.
Knee Surg Relat Res
January 2025
Department of Orthopedics, Seoul National University College of Medicine, Seoul, South Korea.
Introduction: Prosthetic joint infection (PJI) is one of the most common and detrimental complications of total knee replacement arthroplasty (TKA). Despite extensive efforts, including two-stage reimplantation, to eradicate PJI, it still recurs in a substantial number of patients. However, the risk factors of recurrence after two-stage reimplantation of the knee have not been established.
View Article and Find Full Text PDFThe HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial comparing the immunogenicity and safety of the PHH-1V adjuvanted recombinant vaccine as a heterologous booster against homologous booster with BNT162b2. Interim results demonstrated strong humoral and cellular immune response against the SARS-CoV-2 Wuhan-Hu-1 strain and the Beta, Delta, and Omicron BA.1 variants up to day 98 post-dosing.
View Article and Find Full Text PDFAclysiran, an RNAi therapeutic agent targeting ACLY, treats hypercholesterolemia and atherosclerosis in mice.
Acta Pharm Sin B
December 2024
Department of Endocrinology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Effectiveness of the User-Centered "Healthcare CEO" App for Patients With Type 1 Diabetes Transitioning From Adolescence to Early Adulthood: Protocol for a Randomized Controlled Trial.
JMIR Res Protoc
January 2025
Department of Public Health and Primary Care, KU Leuven-University of Leuven, Leuven, Belgium.
Background: Young patients aged 16 to 25 years with type 1 diabetes (T1D) often encounter challenges related to deteriorating disease control and accelerated complications. Mobile apps have shown promise in enhancing self-care among youth with diabetes. However, inconsistent findings suggest that further evidence is necessary to confirm the effectiveness of app-based interventions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!